Introduction {#Sec1}
============

Hospital-acquired pneumonia (HAP) is the most common infection in the intensive care unit (ICU) \[[@CR1]\]. In the ICU, HAP is associated with a mortality rate of 20% and with increased duration of mechanical ventilation and ICU and hospital length-of-stay \[[@CR2], [@CR3]\]. The criteria to diagnose pneumonia are shown in Table [1](#Tab1){ref-type="table"} (Fig. [1](#Fig1){ref-type="fig"}). Table 1Criteria for defining pneumoniaRadiological signs Two successive chest radiographs showing new or progressive lung infiltrates\
 In the absence of medical history of underlying heart or lung disease, a single chest radiograph is enoughAnd at least one of the following signs Body temperature \> 38,3 °C without any other cause\
 Leucocytes \< 4000/mm^3^ or ≥ 12,000/mm^3^And at least two of the following signs Purulent sputum\
 Cough or dyspnoea\
 Declining oxygenation or increased oxygen requirement or need for respiratory assistance Fig. 1Multimodal healthcare associated pneumonia prevention protocol (expert opinion)

Method {#Sec2}
======

Sixteen French-speaking experts produce guidelines in three specific areas related to HAP: prevention, diagnosis and treatment as well as the specificities pertaining to different identified patient populations (COPD, neutropenia, post-operative and paediatric). The schedule of the group was defined upstream (Table [2](#Tab2){ref-type="table"}) (Fig. [2](#Fig2){ref-type="fig"}).Table 2Guideline timeline5 December 2016Start-up meeting6 March 2017Vote: first round13 March 2017Post-vote deliberation meeting1 April 2017Vote: second round16 April 2017Amendment of two guidelines28 April 2017Vote of the two amended guidelines10 May 2017Guideline finalisation meeting Fig. 2Selective digestive decontamination protocol (expert opinion)

The questions were formulated according to the PICO (Patient, Intervention, Comparison, Outcome) format. The formulation of the guidelines was conducted according to the GRADE methodology (Grade of Recommendation Assessment, Development and Evaluation) \[[@CR4], [@CR5]\]. In the absence of supporting literature, a question could be addressed by a recommendation under the form of an expert opinion ("the experts suggest that...") (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Diagnostic procedure (expert opinion)

These guidelines with their arguments were published in the journal Anaesthesia Critical Care and Pain Medicine \[[@CR6]\] (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Treatment options (expert opinion)

**First area, PREVENTION** Which HAP prevention approaches decrease morbidity and mortality in ICU patients? R1.1We recommend using a standardised multimodal HAP prevention approach in order to decrease ICU patient morbidity (Grade 1+).R1.1 PaediatricsWe suggest using a standardised multimodal approach aiming at preventing HAP in order to decrease paediatric ICU patient morbidity (Grade 2+).R1.2In units where multidrug-resistant bacteria prevalence is low (\< 20%), we suggest applying routine selective digestive decontamination using a topical antiseptic administered enterally and a maximal 5-day course of systemic prophylactic antibiotic to decrease mortality (Grade 2+).R1.3Within a standardised multimodal HAP prevention approach, we suggest combining some of the following methods to decrease ICU patient morbidity:Promote the use of non-invasive ventilation to avoid tracheal intubation (mainly in post-operative digestive surgery patients and in patients with COPD),Favour orotracheal over nasotracheal intubation when requiredLimit dose and duration of sedatives and analgesics (promote their use guided by sedation/pain/agitation scales, and/or daily interruptions),Initiate early enteral feeding (within the first 48 h of ICU admission),Regularly verify endotracheal tube cuff pressure,Perform sub-glottic suction (every 6 to 8 h) using an appropriate endotracheal tube (Grade 2+).R1.4Within a standardised multimodal HAP prevention approach, we suggest not using the following methods to decrease ICU patient morbidity:Systematic early (\< day 7) tracheotomy (except for specific indications),Anti-ulcer prophylaxis (except for specific indications),Post-pyloric enteral feeding (except for specific indications),Administration of probiotics and/or synbiotics,Early systematic change of the humidifier filter (except for specific manufacturer recommendations)Use of closed suctioning systems for endotracheal secretions,Use of antiseptic-coated intubation tubes or with tubes an "optimised" cuff shape,Selective oropharyngeal decontamination (SOD) with povidone-iodine,Use of prophylactic nebulised antibiotics,Daily skin decontamination using antiseptics (Grade 2−).R1.5In weaning of COPD patients from ventilation, we suggest using non-invasive ventilation to reduce length of invasive mechanical ventilation, incidence of HAP, morbidity and mortality (Grade 2+).

**Second area, DIAGNOSIS** What methods to diagnose HAP should be used to decrease ICU patient morbidity and mortality? R2.1We suggest not using the clinical scores (CPIS, modified CPIS) for diagnosing HAP (Grade 2−).R2.2We suggest collecting microbiological airway samples, regardless of type, before initiation of any change in antibiotic therapy (Grade 2+).R2.2 PaediatricsWe suggest collecting microbiological airway samples, regardless of type, before initiation of any change in antibiotic therapy (Grade 2+).R2.3We suggest not measuring plasma or alveolar levels of procalcitonin or soluble TREM-1 to diagnose HAP (Grade 2−).

**Third area, TREATMENT** What therapeutic options for HAP should be used to decrease ICU patient morbidity and mortality? R3.1We suggest immediately collecting samples and initiating antibiotic treatment taking into consideration risk factors for multidrug-resistant bacteria in patients with suspected HAP and haemodynamic or respiratory compromise (shock or acute respiratory distress syndrome) or frailty such as immunosuppression \[95--100\] (Grade 2+).R3.2We recommend treating HAP in mechanically ventilated immunocompetent patients empirically by a monotherapy, in the absence of risk factors for multidrug-resistant bacteria, non-fermenting Gram-negative bacilli and/or increased mortality (septic shock, organ failure) \[101--113\] (Grade 1+).R3.3The experts suggest not systematically directing empiric antibiotic therapy against methicillin-resistant *Staphylococcus aureus* in the treatment of HAP \[114--119\] (Experts Opinion).R3.4We suggest reducing the spectrum and preferring monotherapy for the antibiotic therapy of HAP after microbiological documentation, including for non-fermenting Gram-negative bacilli \[114,115, 120--128\] (Grade 2+).R3.5We recommend not prolonging for more than 7 days the antibiotic treatment for HAP, including for non-fermenting Gram-negative bacilli, apart from specific situations (immunosuppression, empyema, necrotising or abscessed pneumonia) \[129--135\] (Grade 1−).R3.6We suggest administering nebulised colimycine (sodium colistiméthate) and/or aminoglycosides in documented HAP due multidrug-resistant Gram-negative bacilli documented pneumonia established as sensitive to colimycin and/or aminoglycoside, when no other antibiotics can be used (based on the results of susceptibility testing) \[136--152\] (Grade 2+).R3.7We recommend not administering statins as adjuvant treatment for HAP \[153--161\] (Grade 1−).
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